{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:59:10Z","timestamp":1793134750682,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Hubei Provincial Natural Science Foundation","award":["No.2023AFD178"],"award-info":[{"award-number":["No.2023AFD178"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-03620-9","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T15:10:51Z","timestamp":1738854651000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The serum hepcidin and the hepcidin\/ferritin ratio in NAFLD: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Jingmin","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiyuan","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxiu","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"issue":"3","key":"3620_CR1","first-page":"195","volume":"26","author":"Fatty Liver Expert Committee CMDA","year":"2018","unstructured":"Fatty Liver Expert Committee CMDA. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: a 2018 update. Zhonghua Gan Zang Bing Za Zhi Zhonghua Ganzangbing Zazhi. Chin J Hepatol. 2018;26(3):195\u2013203.","journal-title":"Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chin J Hepatol"},{"key":"3620_CR2","doi-asserted-by":"crossref","unstructured":">Eslam M, Sanyal AJ, George J, Sanyal A, Neuschwander-Tetri B, Tiribelli C, Kleiner DE, Brunt E, Bugianesi E, Yki-J\u00e4rvinen H. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999\u20132014. e1991.","DOI":"10.1053\/j.gastro.2019.11.312"},{"key":"3620_CR3","doi-asserted-by":"crossref","unstructured":"Amini-Salehi E, Letafatkar N, Norouzi N, Joukar F, Habibi A, Javid M, Sattari N, Khorasani M, Farahmand A, Tavakoli S. Global prevalence of nonalcoholic fatty liver disease: an updated review Meta-analysis comprising a Population of 78 million from 38 countries. Arch Med Res. 2024;55(6):103043.","DOI":"10.1016\/j.arcmed.2024.103043"},{"key":"3620_CR4","doi-asserted-by":"crossref","unstructured":"Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. World J Gastroenterol. WJG2014;20(2):475.","DOI":"10.3748\/wjg.v20.i2.475"},{"key":"3620_CR5","doi-asserted-by":"crossref","unstructured":"Datz C, M\u00fcller E, Aigner E. Iron overload and non-alcoholic fatty liver disease. Minerva Endocrinologica. 2016;42(2):173\u201383.","DOI":"10.23736\/S0391-1977.16.02565-7"},{"key":"3620_CR6","doi-asserted-by":"crossref","unstructured":"Milic S, Mikolasevic I, Orlic L, Devcic E, Starcevic-Cizmarevic N, Stimac D, Kapovic M, Ristic S. The role of iron and iron overload in chronic liver disease. Med Sci Monit: Int Med J Exp Clin Res. 2016;22:2144.","DOI":"10.12659\/MSM.896494"},{"key":"3620_CR7","doi-asserted-by":"crossref","unstructured":"Nemeth E. Ganz T. Hepcidin and iron in health and disease. Annual review of medicine 2023;74:261\u201377.","DOI":"10.1146\/annurev-med-043021-032816"},{"key":"3620_CR8","doi-asserted-by":"crossref","unstructured":"Nemeth E, Ganz, T. Hepcidin-ferroportin interaction controls systemic iron homeostasis. Int J Mol Sci. 2021;22(12):6493.","DOI":"10.3390\/ijms22126493"},{"key":"3620_CR9","doi-asserted-by":"crossref","unstructured":"Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, Chalasani N, Sanyal AJ, Nelson JE. Network NCR Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2012;55(1):77\u201385.","DOI":"10.1002\/hep.24706"},{"key":"3620_CR10","doi-asserted-by":"crossref","unstructured":"Means RT: Iron deficiency and iron deficiency anemia: implications and impact in pregnancy, fetal development, and early childhood parameters. Nutrients. 2020;12(2):447.","DOI":"10.3390\/nu12020447"},{"key":"3620_CR11","doi-asserted-by":"crossref","unstructured":"Kell DB, Pretorius E. Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. Metallomics. 2014;6(4):748\u201373.","DOI":"10.1039\/C3MT00347G"},{"key":"3620_CR12","doi-asserted-by":"crossref","unstructured":"Lombardi R, Pisano G, Fargion S: Role of serum uric acid and ferritin in the development and progression of NAFLD. Int J Mol Sci. 2016;17(4):548.","DOI":"10.3390\/ijms17040548"},{"key":"3620_CR13","doi-asserted-by":"crossref","unstructured":"Kim C-W, Chang Y, Sung E, Shin H, Ryu S: Serum ferritin levels predict incident non-alcoholic fatty liver disease in healthy Korean men. Metabolism. 2012;61(8):1182\u201388.","DOI":"10.1016\/j.metabol.2012.01.007"},{"key":"3620_CR14","doi-asserted-by":"crossref","unstructured":"Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. science. 2004;306(5704):2090\u201393.","DOI":"10.1126\/science.1104742"},{"key":"3620_CR15","doi-asserted-by":"crossref","unstructured":"Tussing-Humphreys L, Pustacioglu C, Nemeth E, Braunschweig, C. Rethinking iron regulation and assessment in iron deficiency, anemia of chronic disease, and obesity: introducing hepcidin. J Acad Nutr Diet. 2012;112(3):391\u2013400.","DOI":"10.1016\/j.jada.2011.08.038"},{"key":"3620_CR16","doi-asserted-by":"crossref","unstructured":"Boga S, Alkim H, Alkim C, Koksal AR, Bayram M, Yilmaz Ozguven MB, Tekin Neijmann S. The relationship of serum hemojuvelin and hepcidin levels with iron overload in nonalcoholic fatty liver disease. J Gastrointestin Liver Dis. 2015;24(3):293\u2013300.","DOI":"10.15403\/jgld.2014.1121.243.hak"},{"key":"3620_CR17","doi-asserted-by":"crossref","unstructured":"Marmur J, Beshara S, Eggertsen G, Onel\u00f6v L, Albiin N, Danielsson O, Hultcrantz R. St\u00e5l P. Hepcidin levels correlate to liver iron content, but not steatohepatitis, in non-alcoholic fatty liver disease. BMC gastroenterol. 2018;18:1\u201310.","DOI":"10.1186\/s12876-018-0804-0"},{"key":"3620_CR18","doi-asserted-by":"crossref","unstructured":"Lyberopoulou A, Chachami G, Gatselis NK, Kyratzopoulou E, Saitis A, Gabeta S, Eliades P, Paraskeva E, Zachou K, Koukoulis GK. Low serum hepcidin in patients with autoimmune liver diseases. PloS one. 2015;10(8):e0135486.","DOI":"10.1371\/journal.pone.0135486"},{"key":"3620_CR19","doi-asserted-by":"crossref","unstructured":"Tan TC, Crawford DH, Franklin ME, Jaskowski LA, Macdonald GA, Jonsson JR, Watson MJ, Taylor PJ, Fletcher LM. The serum hepcidin: ferritin ratio is a potential biomarker for cirrhosis. Liver Int. 2012;32(9):1391\u201399.","DOI":"10.1111\/j.1478-3231.2012.02828.x"},{"key":"3620_CR20","doi-asserted-by":"crossref","unstructured":"Ryan JD, Armitage AE, Cobbold JF, Banerjee R, Borsani O, Dongiovanni P, Neubauer S, Morovat R, Wang LM, Pasricha SR. Hepatic iron is the major determinant of serum ferritin in NAFLD patients. Liver Int. 2018;38(1):164\u201373.","DOI":"10.1111\/liv.13513"},{"key":"3620_CR21","doi-asserted-by":"crossref","unstructured":"Zimmermann A, Zimmermann T, Schattenberg J, P\u00f6ttgen S, Lotz J, Rossmann H, Roeddiger R, Biesterfeld S, Geiss H-C, Schuchmann M. Alterations in lipid, carbohydrate and iron metabolism in patients with non-alcoholic steatohepatitis (NASH) and metabolic syndrome. Eur J Intern Med. 2011;22(3):305\u201310.","DOI":"10.1016\/j.ejim.2011.01.011"},{"key":"3620_CR22","doi-asserted-by":"crossref","unstructured":"Vuppalanchi R, Troutt JS, Konrad RJ, Ghabril M, Saxena R, Bell LN, Kowdley KV, Chalasani N. Serum hepcidin levels are associated with obesity but not liver disease. Obesity. 2014;22(3):836\u201341.","DOI":"10.1002\/oby.20403"},{"issue":"5","key":"3620_CR23","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","volume":"8","author":"D Moher","year":"2010","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Group P: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336\u201341.","journal-title":"Int J Surg"},{"issue":"6","key":"3620_CR24","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1001\/archpsyc.1978.01770300115013","volume":"35","author":"RL Spitzer","year":"1978","unstructured":"Spitzer RL, Endicott J, Robins E. Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry. 1978;35(6):773\u201382.","journal-title":"Arch Gen Psychiatry"},{"issue":"7829","key":"3620_CR25","first-page":"d5928","volume":"343","author":"J Higgins","year":"2011","unstructured":"Higgins J, Altman D, G\u00f8tzsche P, J\u00fcni P, Moher D, Oxman A, Savovic J, Schulz K, Weeks L, Sterne J. Cochrane bias methods group; cochrane statistical methods group. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials BMJ 2011;343(7829):d5928.","journal-title":"Cochrane Collaboration\u2019s tool Assess risk bias Randomised Trials BMJ"},{"key":"3620_CR26","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000."},{"issue":"1","key":"3620_CR27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/jebm.12141","volume":"8","author":"X Zeng","year":"2015","unstructured":"Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F, Niu Y, Du L. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med. 2015;8(1):2\u201310.","journal-title":"J evidence-based Med"},{"issue":"5","key":"3620_CR28","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/jrsm.1429","volume":"11","author":"J Shi","year":"2020","unstructured":"Shi J, Luo D, Weng H, Zeng XT, Lin L, Chu H, Tong T. Optimally estimating the sample standard deviation from the five-number summary. Res Synth Methods. 2020;11(5):641\u201354.","journal-title":"Res Synthesis Methods"},{"key":"3620_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:1\u201313.","journal-title":"BMC Med Res Methodol"},{"issue":"7414","key":"3620_CR30","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Bmj 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"issue":"7650","key":"3620_CR31","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Bmj. 2008;336(7650):924\u201326.","journal-title":"BMJ"},{"issue":"7454","key":"3620_CR32","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","volume":"328","author":"GW Group","year":"2004","unstructured":"Group GW: Grading quality of evidence and strength of recommendations. Bmj 2004, 328(7454):1490.","journal-title":"BMJ"},{"key":"3620_CR33","doi-asserted-by":"crossref","unstructured":"Floreani A, Navaglia F, Rizzotto ER, Basso D, Chiaramonte M, Padoan A, Petridis I, Cazzagon N, Testa R, Marra, M. Mass spectrometry measurement of plasma hepcidin for the prediction of iron overload. Clin Chem Lab Med. 2011;49(2):197\u2013206.","DOI":"10.1515\/CCLM.2011.055"},{"key":"3620_CR34","doi-asserted-by":"crossref","unstructured":"Hoki T, Miyanishi K, Tanaka S, Takada K, Kawano Y, Sakurada A, Sato M, Kubo T, Sato T, Sato Y. Increased duodenal iron absorption through up-regulation of divalent metal transporter 1 from enhancement of iron regulatory protein 1 activity in patients with nonalcoholic steatohepatitis. Hepatology. 2015;62(3):751#x2013;761.","DOI":"10.1002\/hep.27774"},{"key":"3620_CR35","doi-asserted-by":"crossref","unstructured":"Jamali R, Hatami N, Kosari F. The correlation between serum adipokines and liver cell damage in non-alcoholic fatty liver disease. Hepat month. 2016;16(5).","DOI":"10.5812\/hepatmon.37412"},{"key":"3620_CR36","doi-asserted-by":"crossref","unstructured":"Pan X, Chen B, Liu W, Li Y, Hu Z, Lin X, Xu S, Peng X-EJ. Circulating iron levels interaction with central obesity on the risk of nonalcoholic fatty liver disease: a case\u2013control study in Southeast China. Ann Nutr Metab. 2019;74(3):207\u201314.","DOI":"10.1159\/000497228"},{"key":"3620_CR37","doi-asserted-by":"crossref","unstructured":"Senates E, Yilmaz Y, Colak Y, Ozturk O, Altunoz ME, Kurt R, Ozkara S, Aksaray S, Tuncer I, Ovunc. AOK: Serum levels of hepcidin in patients with biopsy-proven nonalcoholic fatty liver disease. Metabolic syndrome related disorders 2011;9(4):287\u201390.","DOI":"10.1089\/met.2010.0121"},{"key":"3620_CR38","doi-asserted-by":"crossref","unstructured":"Pan X, Peng H, Zhang J, Wu Y, Hu Z, Peng X-E. Genetic variants in promoter region of TFR2 is associated with the risk of non-alcoholic fatty liver disease in a Chinese Han population: a case\u2013control study. Gastroenterology Report 2022;10:goac060.","DOI":"10.1093\/gastro\/goac060"},{"key":"3620_CR39","doi-asserted-by":"crossref","unstructured":"Ravasi G, Pelucchi S, Trombini P, Mariani R, Tomosugi N, Modignani GL, Pozzi M, Nemeth E, Ganz T, Hayashi H. Hepcidin expression in iron overload diseases is variably modulated by circulating factors. PloS one. 2012;7(5):e36425.","DOI":"10.1371\/journal.pone.0036425"},{"key":"3620_CR40","doi-asserted-by":"crossref","unstructured":"Uysal S, Armutcu F, Aydogan T, Akin K, Ikizek M, Yigitoglu MR. Some inflammatory cytokine levels, iron metabolism and oxidan stress markers in subjects with nonalcoholic steatohepatitis. Clin Biochem. 2011;44(17-18):1375\u20139.","DOI":"10.1016\/j.clinbiochem.2011.09.017"},{"key":"3620_CR41","doi-asserted-by":"crossref","unstructured":"Farrell GC, Van Rooyen D, Gan L, Chitturi S. NASH is an inflammatory disorder: pathogenic, prognostic and therapeutic implications. Gut liver. 2012;6(2):149.","DOI":"10.5009\/gnl.2012.6.2.149"},{"key":"3620_CR42","doi-asserted-by":"crossref","unstructured":"Gehrke N, Schattenberg JM: Metabolic inflammation\u2014a role for hepatic inflammatory pathways as drivers of comorbidities in nonalcoholic fatty liver disease? Gastroenterology. 2020;158(7):1929\u20131947. e1926.","DOI":"10.1053\/j.gastro.2020.02.020"},{"key":"3620_CR43","doi-asserted-by":"crossref","unstructured":"Huang Y-H, Chuang J-H, Yang Y-L, Huang C-C, Wu C-L, Chen C-.: Cholestasis Downregulate hepcidin expression through inhibiting IL-6-induced phosphorylation of signal transducer and activator of transcription 3 signaling. Lab Invest. 2009;89(10):1128\u201339.","DOI":"10.1038\/labinvest.2009.82"},{"key":"3620_CR44","doi-asserted-by":"crossref","unstructured":"Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, Vaulont S. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci. 2001;98(15):8780\u20135.","DOI":"10.1073\/pnas.151179498"},{"key":"3620_CR45","doi-asserted-by":"crossref","unstructured":"Jung UJ, Choi M-S. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci. 2014;15(4):6184\u2013223.","DOI":"10.3390\/ijms15046184"},{"key":"3620_CR46","doi-asserted-by":"crossref","unstructured":"Hilton C, Sabaratnam R, Drakesmith H, Karpe F. Iron, glucose and fat metabolism and obesity: an intertwined relationship. Int J Obes. 2023;47(7):554\u201363.","DOI":"10.1038\/s41366-023-01299-0"},{"key":"3620_CR47","doi-asserted-by":"crossref","unstructured":"Mitsuyoshi H, Yasui K, Harano Y, Endo M, Tsuji K, Minami M, Itoh Y, Okanoue T, Yoshikawa T. Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease. Hepatol Res. 2009;39(4):366\u201373.","DOI":"10.1111\/j.1872-034X.2008.00464.x"},{"key":"3620_CR48","doi-asserted-by":"crossref","unstructured":"Barisani D, Pelucchi S, Mariani R, Galimberti S, Trombini P, Fumagalli D, Meneveri R, Nemeth E, Ganz T, Piperno A. Hepcidin and iron-related gene expression in subjects with dysmetabolic hepatic Iron overload. J Hepatol. 2008;49(1):123\u201333.","DOI":"10.1016\/j.jhep.2008.03.011"},{"key":"3620_CR49","doi-asserted-by":"crossref","unstructured":"Le Guenno G, Chans\u00e9aume E, Ruivard M, Morio B, Mazur A. Study of iron metabolism disturbances in an animal model of insulin resistance. Diabetes Res Clin Pract. 2007;77(3):363\u201370.","DOI":"10.1016\/j.diabres.2007.02.004"},{"key":"3620_CR50","doi-asserted-by":"crossref","unstructured":"Sam A, Busbridge M, Amin A, Webber L, White D, Franks S, Martin N, Sleeth M, Ismail N, Daud NM. Hepcidin levels in diabetes mellitus and polycystic ovary syndrome. Diabet Med. 2013;30(12):1495\u201399.","DOI":"10.1111\/dme.12262"},{"key":"3620_CR51","doi-asserted-by":"crossref","unstructured":"Fontes-Cal TC, Mattos RT, Medeiros NI, Pinto BF, Belchior-Bezerra M, Roque-Souza B, Dutra WO, Ferrari TC, Vidigal PV, Faria LC. Crosstalk between plasma cytokines, inflammation, and liver damage as a new strategy to monitoring NAFLD progression. Front Immunol. 2021;12:708959.","DOI":"10.3389\/fimmu.2021.708959"},{"key":"3620_CR52","doi-asserted-by":"crossref","unstructured":"Schmidt PJ. Regulation of iron metabolism by hepcidin under conditions of inflammation. J Biol Chem. 2015;290(31):18975\u201383.","DOI":"10.1074\/jbc.R115.650150"},{"key":"3620_CR53","doi-asserted-by":"crossref","unstructured":"Chung B, Matak P, McKie AT, Sharp P. Leptin increases the expression of the iron regulatory hormone hepcidin in HuH7 human hepatoma cells. J Nutr. 2007;137(11):2366\u201370.","DOI":"10.1093\/jn\/137.11.2366"},{"key":"3620_CR54","doi-asserted-by":"crossref","unstructured":"Aigner E, Theurl I, Theurl M, Lederer D, Haufe H, Dietze O, Strasser M, Datz C, Weiss G. Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. Am J Clin Nutr. 2008;87(5):1374\u201383.","DOI":"10.1093\/ajcn\/87.5.1374"},{"key":"3620_CR55","doi-asserted-by":"crossref","unstructured":"Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz, T. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Investig. 2004;113(9):1271\u201376.","DOI":"10.1172\/JCI20945"},{"key":"3620_CR56","doi-asserted-by":"crossref","unstructured":"Lee P, Peng H, Gelbart T, Beutler, E. The IL-6-and lipopolysaccharide-induced transcription of hepcidin in HFE-, transferrin receptor 2-, and \u03b22-microglobulin-deficient hepatocytes. Proc Natl Acad Sci. 2004;101(25):9263\u20135.","DOI":"10.1073\/pnas.0403108101"},{"key":"3620_CR57","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.cca.2021.10.032","volume":"523","author":"S Rana","year":"2021","unstructured":"Rana S, Prabhakar N: Iron disorders and hepcidin. Clinica chimica acta; Int J Clin Chem Sci. 2021;523:454\u201368.","journal-title":"Clin Chim Acta"},{"issue":"7","key":"3620_CR58","doi-asserted-by":"publisher","first-page":"e40465","DOI":"10.1371\/journal.pone.0040465","volume":"7","author":"Y Ikeda","year":"2012","unstructured":"Ikeda Y, Tajima S, Izawa-Ishizawa Y, Kihira Y, Ishizawa K, Tomita S, Tsuchiya K, Tamaki T. Estrogen regulates hepcidin expression via GPR30-BMP6-dependent signaling in hepatocytes. PloS one. 2012;7(7):e40465.","journal-title":"PLoS ONE"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03620-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-03620-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03620-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T15:11:06Z","timestamp":1738854666000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-03620-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3620"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-03620-9","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study adhered to ethical standards by following the PRISMA guidelines for systematic reviews and meta-analyses, ensuring transparency in methodology and the reporting of findings.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}